Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...
SHINE25d
City's doctor the first in Asia to win leading medical award
His team successfully developed a genetic medicine targeting deafness due to OTOF genetic mutation with a precise and minimally invasive drug delivery route and equipment. It is the world's first ...
BioSpace26d
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity
SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...
BioSpace1mon
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
However, otoferlin-related hearing loss is ultra-rare. This specific condition is caused by variants in the OTOF gene, which leads to a lack of a functional otoferlin protein that is critical for the ...
Business Wire1mon
Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial
The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric ...
Frontiers4y
Overloaded Adeno-Associated Virus as a Novel Gene Therapeutic Tool for Otoferlin-Related Deafness
Two cages were run in parallel: one with two male Otof-KO siblings, and one with five Otof-KO females (age 14.4 ± 2.4 weeks), all with a successful ABR rescue (click threshold 50 dB). Sex matched WT ...